SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (Nasdaq: SABS) is a clinical-stage biopharmaceutical company focused on developing fully human polyclonal antibody therapeutics through its proprietary DiversitAb platform, which uses transchromosomic cattle to produce human immunoglobulins. The company became publicly listed in November 2021 through a business combination with Big Rock Partners Acquisition Corp, a blank-check vehicle sponsored by Big Rock Partners LLC. Operating in the biotechnology sector, SAB's pipeline has targeted infectious diseases including COVID-19, with SAB-185 among its lead investigational candidates. The company's August 2026 Form 424B3 prospectus supplement reflects continued registered capital markets activity for the post-merger entity. Visit SpacDesk and sign up for full filing history, pipeline timelines, and SPAC merger analytics on SABS.